Glamatic Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 15-12-2024
- Paid Up Capital ₹ 1.00 M
as on 15-12-2024
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.00 M
as on 15-12-2024
- Revenue %
(FY 2021)
- Net Worth -3.43%
(FY 2021)
- Total Assets -5.25%
(FY 2021)
About Glamatic Pharmaceuticals
The Corporate was formerly known as Glamatic Enterprises Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹4.00 M.
Pabitra Bhowmik, Paramita Bhowmik, and Siddharth Bhowmik serve as directors at the Company.
- CIN/LLPIN
U24100TG2019PTC135942
- Company No.
135942
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Oct 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Glamatic Pharmaceuticals Private Limited offer?
Glamatic Pharmaceuticals Private Limited offers a wide range of products and services, including Surgical & ICU Equipments, Defibrillators, Diagnostic Medical Imaging Equipment, ECG Machine, Hospital and Medical Furniture, Hospital Bed and Mattress, Syringe Pump, Hospital Tables, Medical Trolley, OT Tables.
Who are the key members and board of directors at Glamatic Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pabitra Bhowmik  | Director | 12-Aug-2021 | Current |
| Paramita Bhowmik | Director | 12-Aug-2021 | Current |
| Siddharth Bhowmik | Director | 04-Jan-2022 | Current |
Financial Performance of Glamatic Pharmaceuticals.
Glamatic Pharmaceuticals Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth dipped by a decrease of 3.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Glamatic Pharmaceuticals?
In 2021, Glamatic Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 11 Jul 2023 | ₹4.00 M | Open |
How Many Employees Work at Glamatic Pharmaceuticals?
Glamatic Pharmaceuticals has a workforce of 15 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Glamatic Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Glamatic Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
